Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease

Journal of Scleroderma and Related Disorders

Volumn 4, Issue 3, 2019, Pages 212-218

  Wollin, Lutz ^a   Distler, Jörg HW ^b   Denton, Christopher P ^c   Gahlemann, Martina ^d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Boehringer Ingelheim (Schweiz) Gmbh   (Switzerland)

Author keywords

Fibroblasts; fibrosis; scleroderma; systemic sclerosis associated interstitial lung disease; tyrosine kinase inhibitor

Indexed keywords

EID: 85064821521     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.1177/2397198319841842     Document Type: Review

References (61)

1. Rubio-Rivas M Royo C Simeón CP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44(2): 208–219.
2. Allanore Y Simms R Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers 2015; 1: 15002.
3. Denton CP Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685–1699.
4. Matucci-Cerinic M Krieg T Guillevin L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 2016; 75(10): 1770–1776.
5. Hudson M Thombs BD Steele R, et al. Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 2008; 59(2): 279–284.
6. Tyndall AJ Bannert B Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69(10): 1809–1815.
7. Baron M Sutton E Hudson M, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67(5): 644–650.
8. Khanna D Tseng CH Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63(10): 3078–3085.
9. Jaeger VK Wirz EG Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE 2016; 11(10): e0163894.
10. Herzog EL Mathur A Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66(8): 1967–1978.
11. Tomiyama F Watanabe R Ishii T, et al. High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis. Tohoku J Exp Med 2016; 239(4): 297–305.
12. Collard HR Ryerson CJ Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016; 194(3): 265–275.
13. Fernandez-Codina A Walker KM Pope JE; Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70(11): 1820–1828.
14. Adler S Huscher D Siegert E, et al. Systemic sclerosis associated interstitial lung disease—individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 2018; 20(1): 17.
15. Tashkin DP Elashoff R Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.
16. Tashkin DP Roth MD Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4(9): 708–719.
17. Kowal-Bielecka O Fransen J Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76(8): 1327–1339.
18. Eyraud A Scouppe L Barnetche T, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of literature. Br J Dermatol 2018; 178: 650–658.
19. Khanna D Tashkin DP Denton CP, et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology. Epub ahead of print 8 June 2018. DOI: 10.1093/rheumatology/key151.
20. Denton CP Black CM Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2(3): 134–144.
21. Pattanaik D Brown M Postlethwaite BC, et al. Pathogenesis of systemic sclerosis. Front Immunol 2015; 6: 272.
22. Distler O Del Rosso A Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4(6): R11.
23. Distler O Distler JH Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95(1): 109–116.
24. Albert ML Jegathesan M Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2(11): 1010–1017.
25. Tsuji S Kaji K Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J Biochem 1994; 116(4): 794–800.
26. Greeno EW Bach RR Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75(2): 281–289.
27. Stifano G Christmann RB. Macrophage involvement in systemic sclerosis: do we need more evidence? Curr Rheumatol Rep 2016; 18(1): 2.
28. Sato S Fujimoto M Hasegawa M, et al. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004; 41(12): 1123–1133.
29. O’Reilly S Hügle T van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology 2012; 51(9): 1540–1549.
30. Klingberg F Hinz B White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol 2013; 229(2): 298–309.
31. Ebmeier S Horsley V. Origin of fibrosing cells in systemic sclerosis. Curr Opin Rheumatol 2015; 27(6): 555–562.
32. Bagnato G Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015; 24(135): 102–114.
33. Wollin L Wex E Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45(5): 1434–1445.
34. Hilberg F Roth GJ Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68(12): 4774–4782.
35. Wollin L Maillet I Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349(2): 209–220.
36. Tandon K Herrmann F Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med 2017; 195: A2397.
37. Hilberg F Tontsch-Grunt U Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther 2018; 364(3): 494–503.
38. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15(4): 255–273.
39. Inoue Y King TE Jr Tinkle SS, et al. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996; 149(6): 2037–2054.
40. Barratt SL Flower VA Pauling JD, et al. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int J Mol Sci 2018; 19(5): E1269.
41. Beyer C Distler JH. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta 2013; 1832(7): 897–904.
42. Hu M Che P Han X, et al. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 2014; 351(1): 87–95.
43. Meziani L Mondini M Petit B, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J 2018; 51(3): 1702120.
44. Straus DB Weiss A. Genetic evidence for the involvement of the Lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992; 70(4): 585–593.
45. Ochi H Takeshita H Suda T, et al. Regulation of B-1 cell activation and its autoantibody production by Lyn kinase-regulated signallings. Immunology 1999; 98(4): 595–603.
46. Vancheri C. Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med 2015; 13: 220.
47. Richeldi L Costabel U Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365(12): 1079–1087.
48. Richeldi L du Bois RM Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22): 2071–2082.
49. Sato S Shinohara S Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 2017; 18(1): 172.
50. Sava P Ramanathan A Dobronyi A, et al. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung. JCI Insight 2017; 2(24): e96352.
51. Ackermann M Kim YO Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 2017; 20(3): 359–372.
52. Huang J Beyer C Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016; 75(5): 883–890.
53. Huang J Maier C Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 2017; 76(11): 1941–1948.
54. Wollin L Ostermann A Williams C. Nintedanib inhibits pro-fibrotic mediators with relevance in connective tissue disease-associated interstitial lung diseases. Am J Respir Crit Care Med 2017; 195: A2450.
55. Mross K Stefanic M Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16(1): 311–319.
56. Eisen T Shparyk Y Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs 2013; 31(5): 1283–1293.
57. Distler O Brown KK Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol 2017; 35: 75–81.
58. Leuschner G Stocker F Veit T, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. Epub ahead of print 5 July 2017. DOI: 10.1016/j.healun.2017.07.002.
59. Lambers C Boehm PM Lee S, et al. Effect of antifibrotics on short-term outcome after bilateral lung transplantation. Eur Respir J 2018; 51(6): 1800503.
60. Tuyls S Verleden SE Wuyts WA, et al. Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Transpl Int 2019; 32(4): 399–409.
61. Assassi S Sharif R Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12(5): R166.